BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Germ cell tumor AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Clinical Outcome
26 results:

  • 1. B7-H3 is associated with the armored-cold phenotype and predicts poor immune checkpoint blockade response in melanoma.
    Shen B; Mei J; Xu R; Cai Y; Wan M; Zhou J; Ding J; Zhu Y
    Pathol Res Pract; 2024 Apr; 256():155267. PubMed ID: 38520953
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Diffuse hemispheric glioma with H3 p.K28M (K27M) mutation: Unusual non-midline presentation of diffuse midline glioma, H3 K27M-altered?
    Donev K; Sundararajan V; Johnson D; Balan J; Chambers M; Paulson VA; Scherpelz KP; Abdullaev Z; Quezado M; Cimino PJ; Pratt D; Valerio E; Alves de Castro JV; Carraro DM; Torrezan GT; Wolff BM; Kulikowski LD; Costa FD; Aldape K; Ida CM
    J Neuropathol Exp Neurol; 2024 Apr; 83(5):357-364. PubMed ID: 38447592
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Updates in the classification of ependymal neoplasms: The 2021 WHO Classification and beyond.
    Kresbach C; Neyazi S; Schüller U
    Brain Pathol; 2022 Jul; 32(4):e13068. PubMed ID: 35307892
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Thalamic gliomas in adults: a systematic review of clinical characteristics, treatment strategies, and survival outcomes.
    Palmisciano P; El Ahmadieh TY; Haider AS; Bin Alamer O; Robertson FC; Plitt AR; Aoun SG; Yu K; Cohen-Gadol A; Moss NS; Patel TR; Sawaya R
    J Neurooncol; 2021 Dec; 155(3):215-224. PubMed ID: 34797525
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. NCAPG2 facilitates glioblastoma cells' malignancy and xenograft tumor growth via HBO1 activation by phosphorylation.
    Wu J; Li L; Jiang G; Zhan H; Zhu X; Yang W
    Cell Tissue Res; 2021 Feb; 383(2):693-706. PubMed ID: 32897418
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome.
    Jünger ST; Andreiuolo F; Mynarek M; Dörner E; Zur Mühlen A; Rutkowski S; von Bueren AO; Pietsch T
    Childs Nerv Syst; 2020 Nov; 36(11):2693-2700. PubMed ID: 32474813
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Significance of H3K27M Mutation in "Nonmidline" High-Grade Gliomas of Cerebral Hemispheres.
    La Rocca G; Sabatino G; Altieri R; Signorelli F; Ricciardi L; Gessi M; Della Pepa GM
    World Neurosurg; 2019 Nov; 131():174-176. PubMed ID: 31415896
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Overview of DNA methylation in adult diffuse gliomas.
    Aoki K; Natsume A
    Brain Tumor Pathol; 2019 Apr; 36(2):84-91. PubMed ID: 30937703
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Malignant primary diffuse leptomeningeal gliomatosis with histone H3.3 K27M mutation.
    Champeaux C; Drier A; Devaux B; Tauziède-Espariat A
    Neurochirurgie; 2018 Jun; 64(3):198-202. PubMed ID: 29752148
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
    Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
    Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Significance of H3K27me3 loss in the diagnosis of malignant peripheral nerve sheath tumors.
    Pekmezci M; Cuevas-Ocampo AK; Perry A; Horvai AE
    Mod Pathol; 2017 Dec; 30(12):1710-1719. PubMed ID: 28776579
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Update on the 2016 WHO classification of tumors of the central nervous system - Part 1: Diffusely infiltrating gliomas].
    Švajdler M; Rychlý B; Zámečník J; Švajdler P
    Cesk Patol; 2017; 53(1):12-21. PubMed ID: 28248117
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
    Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
    Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes.
    Castel D; Philippe C; Calmon R; Le Dret L; Truffaux N; Boddaert N; Pagès M; Taylor KR; Saulnier P; Lacroix L; Mackay A; Jones C; Sainte-Rose C; Blauwblomme T; Andreiuolo F; Puget S; Grill J; Varlet P; Debily MA
    Acta Neuropathol; 2015 Dec; 130(6):815-27. PubMed ID: 26399631
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III.
    Varughese RK; Lind-Landström T; Habberstad AH; Salvesen Ø; Haug CS; Sundstrøm S; Torp SH
    J Clin Pathol; 2016 Jan; 69(1):26-34. PubMed ID: 26188054
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities.
    Reuss DE; Kratz A; Sahm F; Capper D; Schrimpf D; Koelsche C; Hovestadt V; Bewerunge-Hudler M; Jones DT; Schittenhelm J; Mittelbronn M; Rushing E; Simon M; Westphal M; Unterberg A; Platten M; Paulus W; Reifenberger G; Tonn JC; Aldape K; Pfister SM; Korshunov A; Weller M; Herold-Mende C; Wick W; Brandner S; von Deimling A
    Acta Neuropathol; 2015 Sep; 130(3):407-17. PubMed ID: 26087904
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. αvβ3 Integrin and Fibroblast growth factor receptor 1 (fgfr1): Prognostic factors in a phase I-II clinical trial associating continuous administration of Tipifarnib with radiotherapy for patients with newly diagnosed glioblastoma.
    Ducassou A; Uro-Coste E; Verrelle P; Filleron T; Benouaich-Amiel A; Lubrano V; Sol JC; Delisle MB; Favre G; Ken S; Laprie A; De Porre P; Toulas C; Poublanc M; Cohen-Jonathan Moyal E
    Eur J Cancer; 2013 Jun; 49(9):2161-9. PubMed ID: 23566417
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immunodetection of phosphohistone H3 as a surrogate of mitotic figure count and clinical outcome in cutaneous melanoma.
    Tetzlaff MT; Curry JL; Ivan D; Wang WL; Torres-Cabala CA; Bassett RL; Valencia KM; McLemore MS; Ross MI; Prieto VG
    Mod Pathol; 2013 Sep; 26(9):1153-60. PubMed ID: 23558574
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas.
    Khuong-Quang DA; Buczkowicz P; Rakopoulos P; Liu XY; Fontebasso AM; Bouffet E; Bartels U; Albrecht S; Schwartzentruber J; Letourneau L; Bourgey M; Bourque G; Montpetit A; Bourret G; Lepage P; Fleming A; Lichter P; Kool M; von Deimling A; Sturm D; Korshunov A; Faury D; Jones DT; Majewski J; Pfister SM; Jabado N; Hawkins C
    Acta Neuropathol; 2012 Sep; 124(3):439-47. PubMed ID: 22661320
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Proliferative and metabolic markers in incompletely excised pediatric pilocytic astrocytomas--an assessment of 3 new variables in predicting clinical outcome.
    Margraf LR; Gargan L; Butt Y; Raghunathan N; Bowers DC
    Neuro Oncol; 2011 Jul; 13(7):767-74. PubMed ID: 21653594
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.